Numerous clinical studies have reported that St. John’s wort is more effective than placebo, with results similar to SSRIs.
A study at the University of Vienna analyzed three double-blind trials that included 544 out-patients suffering from mild to moderate depression
who received St. John’s wort or placebo. Researchers concluded that St. John’s wort reduced the symptoms of depression more effectively than
placebo and accelerated the recovery from depression.
One review of 23 randomized trials that included a total of 1,757 outpatients with mainly mild to moderately severe depressive disorders noted
that here was “evidence that extracts of hypericum are more effective than placebo for the treatment of mild to moderately severe depressive
disorders."
Other double-blind, placebo-controlled studies have examined the effectiveness of St. John's wort for the treatment of mild to moderate major
depression, and most have found the herb at least as effective as antidepressant medications. St. John’s wort extract has been compared favorably
to the prescription antidepressants paroxetine (Paxil), citalopram (Celexa), imipramine (Tofranil), amitriptyline (Elavil),
fluoxetine (Prozac), maprotiline (Ludiomil), and sertraline (Zoloft). In these studies, the improvement in depressive symptoms in people
taking St. John’s wort was similar or better than the antidepressants, often with far fewer side effects.
One clinical trial compared a higher amount of the St. John’s wort with imipramine in severely depressed patients. The overall improvement
of both groups was virtually the same with far fewer side effects for the St. John’s wort group.
Hyperforin is a natural compound extracted from the St. John's wort plant that is the primary compound responsible for its antidepressant effects.
Biochemical studies have demonstrated that hyperforin works similarly to many prescription antidepressants by inhibiting the reuptake of the
neurotransmitters norepinephrine, serotonin, and dopamine. All three of these neurotransmitters are chemical messengers that transmit information
between nerve cells. An imbalance of serotonin, norepinephrine, and/or dopamine can cause depression. By acting as a "reuptake inhibitor" in the
same manner that an antidepressant would, hyperforin increases the levels of these neurotransmitters in the brain, which can reduce the symptoms of
depression.
An extensive body of research, consisting of over 30 controlled clinical trials, has proven the effectiveness of hyperforin-rich St. John's wort
extract for elevating mood and relieving depression.
A 2005 German study established that hyperforin was superior to the prescription drug paroxetine (Paxil) as a treatment for severe depression.
Additionally, adverse side effects occur less frequently with hyperforin than prescription antidepressants.
The German Commission E recognized Hypericum Perforatum (the dried parts from above the ground) as an herb approved for use in 1984.
Since then, St. John's wort has been so commonly used as an antidepressant in Germany that it is estimated to be prescribed as much as four times
more often than fluoxetine (Paxil).
St. John’s wort has been popular in the U.S. as well, with 1997 sales topping $45 million. In response, the United States Pharmacopoeia/
National Formulary published both a monograph and compendial standard for St. John’s wort in an attempt to create quality standards.
While studies worldwide point to St. John’s wort as effective for depression, treatment should be done under the guidance of a healthcare
professional. One of the problems with trying to determine the efficacy of any supplement, herb, or antidepressant is that they all react
differently in each person. This variable can be pronounced in people with depressive disorders,
further enforcing the need for a qualified medical evaluation.
Behnke K, Jensen GS, Graubaum HJ, Gruenwald J. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Adv Ther 2002 Jan-Feb;19(1): 43–52.
Bjerkenstedt L, Edman GV, Alken RG, Mannel M. Hypericum extract LI 160 and fluoxetine in mild to moderate depression. A randomized, placebo-controlled multi-center study in outpatients. Eur Arch Psychiatry Clin Neurosci 2005 Feb;255(1): 40–7.
Brenner R, Azbel V, Madhusoodanan S, Pawlowska M. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clinical Therapeutics 2000;22(4): 411–9.
Blumenthal M, Busse WR, Goldberg A, Gruenwald J, Hall T, Klien RS, Riggins CW, Rister RS (eds). The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Austin, TX: American Botanical Council; Boston: Integrative Medicine Communications, 1998.
Ernst E. St. John’s wort, an antidepressant? A systemic, criteria-based review. Phytomedicine 1995;2: 67–71.
Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, Murck H, Rosenbaum JF. A double-blind, randomized trial of St. John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol 2005 Oct;5(5): 441–7.
Fredricks, R. (2008). Healing & wholeness: Complementary and alternative therapies for mental health. Bloomington, IN: Author House.
Friede M, Henneicke von Zepelin HH, Freudenstein J. Differential therapy of mild to moderate depressive episodes (ICD-10 F 32.0; F 32.1) with St. John's wort. Pharmacopsychiatry 2001;34: S38–41.
Gaster B, Holroyd J. St John's wort for depression: A systematic review. Arch Intern Med 2000;160(2): 152–6.
Gastpar M, Singer A, Zeller K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: A double-blind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatry 2006;39: 66–75.
Gastpar M, Singer A, Zeller K. Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry 2005;38(2): 78–86.
Harrer G, Hübner WD, Poduzweit H. Effectiveness and tolerance of the Hypericum extract LI 160 compared to maprotiline: A multicenter double-blind study. J Geriatr Psychiatry Neurol 1994;7: S24–8.
Harrer G, Schmidt U, Kuhn U, Biller A. Comparison of equivalence between the St. John’s wort extract LoHyp-57 and fluoxetine. Arzneimittelforschung 1999;49: 289–96.
Harrer G, Sommer H. Treatment of mild/moderate depressions with Hypericum. Phytomedicine 1994;1: 3–8.
Holzl J. Constituents and mechanism of action of St. John's wort. Zeitschrift Phytother 1993;14: 255–64.
Kalb R, Trautmann-Sponsel RD, Kieser M. Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial. Pharmacopsychiatry 2001;34: 96–103.
Kasper S, Anghelescu I, Szegedi A, Dienel A, Kieser M. Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]. BMC Med 2006 Jun;4: 14.
Kasper S, Dienel A. Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients. A meta-analysis of data from three randomized, placebo-controlled trials. Psychopharmacology 2002;3: 301–8.
Laakmann G, Jahn G, Schule C. Hypericum perforatum extract in treatment of mild to moderate depression. Clinical and pharmacological aspects. Nervenarzt 2002;73(7): 600–12.
Laakmann G, Schule C, Baghai T, Kieser M. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 1998 Jun;31(suppl): 54–9.
Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St. John's wort for depression--An overview and meta-analysis of randomized clinical trials. BMJ 1996 Aug;313(7052): 253–8.
Muller WE, Rossol R. Effects of Hypericum extract on the expression of serotonin receptors. J Geriatr Psychiatry Neurol 1994;7(1): S63–4.
Muruganandam AV, Bhattacharya SK, Ghosal S. Antidepressant activity of hyperforin conjugates of the St. John's wort, hypericum perforatum linn.: An experimental study. Indian J Exp Biol 2001 39(12): 1302–4.
NIH. NIH to explore St. John''s Wort. Science 1997;278: 391.
Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: Randomised multicentre study of treatment for eight weeks. BMJ 1999;319: 1534–9.
Schrader D. Equivalence of St. John’s wort extract (ZE 117) and fluoxetine: A randomized, controlled study in mild – moderate depression. International Clin Psychopharmacol 2000;15: 61–8.
Schrader E, Meier B, Brattstrom A. Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicentre study. Hum Psychopharmacol 1998;13: 163–9
Schulz V. Clinical trials with hypericum extracts in patients with depression--results, comparisons, conclusions for therapy with antidepressant drugs. Phytomedicine 2002;9(5): 468–74.
Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: A randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 2000;15: 61–8.
Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, Russell J, Lydiard RB, Crits-Cristoph P, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl SM, Halbreich U. Effectiveness of St. John's wort in major depression: a randomized controlled trial. JAMA 2001 Apr;285(15): 1978–86.
Szegedi A, Kohnen R, Dienel A, Kieser M. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): Randomised controlled double blind non-inferiority trial versus paroxetine. BMJ 2005;330: 503.
Teufel-Mayer R, Gleitz J. Effects of long-term administration of hypericum extracts on the affinity and density of the central serotonergic 5-HT1 A and 5-HT2 A receptors. Pharmacopsychiatry 1997;30(suppl 2): 113–6.
Uebelhack R, Gruenwald J, Graubaum HJ, Busch R. Efficacy and tolerability of Hypericum extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebo-controlled clinical trial. Adv Ther 2004 Jul-Aug;21(4): 265–75.
van Gurp G, Meterissian GB, Haiek LN, McCusker J, Bellavance F. St John's wort or sertraline? Randomized controlled trial in primary care. Can Fam Physician 2002 May;48: 905–12.
Volz HP, Laux P. Potential treatment for subthreshold and mild depression: A comparison of St. John’s wort extracts and fluoxetine. Compr Psychiatry 2000;41(2): 133–7.
Vorbach EU, Arnoldt KH, Hübner WD. Efficacy and tolerability of St. John’s wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry 1997;30: 81–5.
Vorbach EU, Hübner WD, Arnoldt KH. Effectiveness and tolerance of the Hypericum extract LI 160 in comparison with imipramine: Randomized double-blind study with 135 outpatients. J Geriatr Psychiatry Neurol 1994;7(suppl): S19–23.
Woelk H. Comparison of St. John’s wort and imipramine for treating depression: Randomized controlled trial. BMJ 2000;321: 536–9.
Wheatley D. LI 160, an extract of St. John’s wort versus amitriptyline in mildly to moderately depressed outpatients-controlled six week clinical trial. Pharmacopsychiatry 1997;30: 77–80.
Whiskey E, Werneke U, Taylor D. A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review. Int Clin Psychopharmacol 2001 Sep;16(5): 239–52.
US Pharmacopeia Press Release: AMA Recognizes USP Role in Establishing Quality of Herbal Product. December 16, 1998.
US Pharmacopeia Press Release: USP Publishes Nine New Botanical Monographs. The Standard of Quality in Promoting the Public Health November 2, 1998.